Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis Sees India As Major Site For Diabetes Treatments

This article was originally published in PharmAsia News

Executive Summary

France's Sanofi-Aventis sees India as a possible base for the company's global effort to be a major player in diabetes treatments. In addition to beginning research into India-specific drug combinations and marketing of its Apidra (glulisine recombinant) insulin in India later this year, the firm also may make the country a global hub for its insulin manufacturing. The French drug maker already has a 7.9 percent market share for oral diabetes drugs and insulin through its Indian arm, Aventis Pharma. The subsidiary relies on a large Indian market for combination drugs, spurring the move to India-specific treatments. (Click here for more

Related Content

Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts